Last Price$63.00.0%
Market Cap$4,674.2M
LTM Research & Development Expenses (R&D)
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
385.7% undervalued
M.D.C. Holdings, Inc. Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for MDC
and see if it's the right time to invest.
M.D.C. Holdings, Inc. (MDC) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
M.D.C. Holdings, Inc.MDC
$0.0
N/A
N/A
N/A
Median Peer Set
$0.0
0.0%
0.0%
0.0%
D.R. Horton, Inc.DHI
$0.0
N/A
N/A
N/A
KB HomeKBH
$0.0
N/A
N/A
N/A
Lennar CorporationLEN
$0.0
N/A
N/A
N/A
Meritage Homes CorporationMTH
$0.0
N/A
N/A
N/A
PulteGroup, Inc.PHM
$0.0
N/A
N/A
N/A
Skyline Champion CorporationSKY
$0.0
N/A
N/A
N/A
Cavco Industries, Inc.CVCO
$0.0
N/A
N/A
N/A
Toll Brothers, Inc.TOL
$0.0
N/A
N/A
N/A
NVR, Inc.NVR
$0.0
N/A
N/A
N/A
Taylor Morrison Home CorporationTMHC
$0.0
N/A
N/A
N/A
MDC key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 4,009.1 0.0% | 4,884.2 21.8% | 4,801.7 (1.7%) | 2,933.2 (38.9%) | 1,458.1 (50.3%) | 898.3 (38.4%) | 958.7 6.7% | 844.2 (11.9%) | 1,203.0 42.5% | 1,680.4 39.7% | 1,694.6 0.8% | 1,909.0 12.7% | 2,326.8 21.9% | 2,577.6 10.8% | 3,065.2 18.9% | 3,293.3 7.4% | 3,901.2 18.5% | 5,254.7 34.7% | 5,718.0 8.8% | 122.6 (97.9%) |
| Cost of Goods Sold (COGS) | 3,270.6 | 3,955.4 | 3,653.1 | 2,440.0 | 1,238.7 | 711.9 | 750.5 | 697.5 | 1,000.7 | 1,365.1 | 1,392.3 | 1,583.6 | 1,930.4 | 2,122.8 | 2,475.2 | 2,646.1 | 3,035.1 | 3,990.2 | 4,407.6 | (683.5) |
% margin | 738.5 18.4% | 928.8 19.0% | 1,148.6 23.9% | 493.3 16.8% | 219.4 15.0% | 186.4 20.8% | 208.2 21.7% | 146.7 17.4% | 202.3 16.8% | 315.3 18.8% | 302.3 17.8% | 325.5 17.0% | 396.5 17.0% | 454.8 17.6% | 590.0 19.2% | 647.1 19.6% | 866.1 22.2% | 1,264.5 24.1% | 1,310.4 22.9% | 806.1 657.7% |
| Operating Expenses | 101.6 | 120.0 | 703.4 | 523.1 | 320.9 | 236.5 | 245.7 | 210.3 | 167.3 | 213.3 | 203.3 | 226.3 | 250.5 | 287.5 | 329.8 | 362.8 | 403.2 | 494.0 | 536.4 | 429.9 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 101.6 | 120.0 | 703.4 | 523.1 | 320.9 | 230.9 | 242.6 | 205.1 | 167.3 | 213.3 | 203.3 | 226.3 | 250.5 | 287.5 | 329.8 | 362.8 | 403.2 | 494.0 | 536.4 | 429.9 |
% margin | 636.9 15.9% | 808.8 16.6% | 445.2 9.3% | (29.8) (1.0%) | (101.5) (7.0%) | (50.1) (5.6%) | (37.5) (3.9%) | (63.6) (7.5%) | 35.0 2.9% | 102.0 6.1% | 99.1 5.8% | 99.1 5.2% | 146.0 6.3% | 167.3 6.5% | 260.2 8.5% | 305.0 9.3% | 457.5 11.7% | 775.3 14.8% | 759.9 13.3% | 376.2 306.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.2 | 26.6 | 30.9 | 26.7 | 30.5 | 29.4 | 10.5 | 10.7 | 11.9 | 12.6 | 9.1 | 4.2 | 6.0 | 10.8 | 86.8 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 38.6 | 38.6 | 21.1 | 0.8 | 1.7 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 63.6 | 61.3 | 72.5 | 17.2 | 69.9 |
| Pre-tax Income | 636.9 | 808.8 | 333.1 | (756.5) | (382.1) | (107.3) | (70.6) | (107.5) | 61.1 | 129.8 | 100.5 | 101.4 | 151.8 | 229.7 | 263.9 | 305.0 | 457.5 | 751.7 | 759.9 | 526.1 |
% effective tax rate | 245.7 38.6% | 303.0 37.5% | 118.9 35.7% | (119.5) 15.8% | (1.6) 0.4% | (132.0) 123.0% | (5.8) 8.3% | (9.1) 8.5% | (1.6) (2.6%) | (184.6) (142.2%) | 37.3 37.2% | 35.6 35.1% | 48.6 32.0% | 87.9 38.3% | 53.1 20.1% | 66.7 21.9% | 89.9 19.7% | 178.0 23.7% | 197.7 26.0% | (125.1) (23.8%) |
% margin | 391.2 9.8% | 505.7 10.4% | 214.3 4.5% | (636.9) (21.7%) | (380.5) (26.1%) | 24.7 2.7% | (64.8) (6.8%) | (98.4) (11.7%) | 62.7 5.2% | 314.4 18.7% | 63.1 3.7% | 65.8 3.4% | 103.2 4.4% | 141.8 5.5% | 210.8 6.9% | 238.3 7.2% | 367.6 9.4% | 573.7 10.9% | 562.1 9.8% | 401.0 327.2% |
| EPS | 5.34 | 8.68 | 3.61 | (10.54) | (6.23) | 0.39 | (1.05) | (1.60) | 0.98 | 4.83 | 0.98 | 1.02 | 1.60 | 2.18 | 3.22 | 3.56 | 5.33 | 8.13 | 7.87 | 5.42 |
| Diluted EPS | 5.11 | 8.31 | 3.52 | (10.54) | (6.23) | 0.39 | (1.05) | (1.60) | 0.98 | 4.79 | 0.98 | 1.01 | 1.59 | 2.13 | 3.16 | 3.44 | 5.17 | 7.83 | 7.67 | 5.29 |
% margin | 678.8 16.9% | 863.6 17.7% | 616.6 12.8% | 744.1 25.4% | 205.8 14.1% | (32.5) (3.6%) | (5.2) (0.5%) | (32.6) (3.9%) | 66.7 5.5% | 135.4 8.1% | 127.5 7.5% | 109.5 5.7% | 158.4 6.8% | 181.7 7.0% | 285.2 9.3% | 328.0 10.0% | 484.7 12.4% | 806.9 15.4% | 787.6 13.8% | 376.2 306.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is M.D.C. Holdings, Inc.'s Research & Development Expenses (R&D)?
As of today, M.D.C. Holdings, Inc.'s last 12-month Research & Development Expenses (R&D) is $0.0, based on the financial report for Mar 31, 2024 (Q1’2024).
2) What is M.D.C. Holdings, Inc.'s Research & Development Expenses (R&D) growth rate?
Over the last year, M.D.C. Holdings, Inc.'s Research & Development Expenses (R&D) growth was N/A. The average annual Research & Development Expenses (R&D) growth rates for M.D.C. Holdings, Inc. have been N/A over the past three years, N/A over the past five years.